Indication
Central Nervous System Tumors
9 clinical trials
11 products
3 drugs
1 abstract
Product
EntrectinibClinical trial
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsStatus: Active (not recruiting), Estimated PCD: 2025-06-15
Product
AvelumabClinical trial
Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS TumorsStatus: Recruiting, Estimated PCD: 2025-12-21
Product
LenvatinibClinical trial
A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) and Other Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-03-01
Product
midazolamProduct
AvapritinibClinical trial
A Clinical Study of Oncolytic Virus (OH2) Injection in the Treatment of Patients Undergoing Surgery After Recurrence of Central Nervous System TumorsStatus: Recruiting, Estimated PCD: 2024-06-16
Clinical trial
A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System TumorsStatus: Completed, Estimated PCD: 2018-07-01
Product
OH2Product
BLZ-100Clinical trial
A Phase I, Open-Label, Single Institution Study to Assess the Safety, Tolerability, and Pharmacokinetics of Durvalumab in Pediatric Patients With Relapsed or Refractory Solid Tumors, Lymphoma, and Central Nervous System TumorsStatus: Completed, Estimated PCD: 2022-11-30
Product
DurvalumabClinical trial
A Multi-Center Phase I Dose Escalation Study of Avutometinib, a RAF/MEK Clamp, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway AlterationsStatus: Recruiting, Estimated PCD: 2029-10-20
Drug
AvutometinibClinical trial
Phase 2 Solid Tumor Immunotherapy Trial Using HLA-Haploidentical Transplant and Donor Natural Killer Cells: The STIR TrialStatus: Completed, Estimated PCD: 2020-06-08
Product
Donor NK CellClinical trial
A Phase I Study Of Irinotecan and Bevacizumab With Temozolomide in Children With Recurrent/Refractory Central Nervous System TumorsStatus: Completed, Estimated PCD: 2015-09-01
Drug
AtezolizumabDrug
FOLFOXIRIProduct
TMZProduct
4-drug combination